Log in to search using one of your social media accounts:

 

Companion Medical launches smart insulin pen in U.S.
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin. Get the full story at our sister site, Drug Delivery Business News. The post Companion Medical launches smart insulin pen in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations mHealth (Mobile Health) Pharmaceuticals Companion Medical Eli Lilly & Co. Novo Nordisk Source Type: news

NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2017 Category: Drugs & Pharmacology Source Type: news

NovoLog Mix 50/50 (50% Insulin Aspart Protamine Suspension and 50% Insulin Aspart Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

NovoLog (Insulin Aspart [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Companion Medical wins FDA nod for InPen insulin pen
Companion Medical said today it won FDA 510(k) approval for its wireless-enabled InPen insulin pen and mobile application. The InPen is designed to connect to smartphones via bluetooth and send data back, including insulin dosage and timing, the company said. The app allows patients to track and calculate doses, and set alarms for future doses. “FDA clearance of the InPen and mobile app represents a significant advancement in diabetes care. The product combines the benefits of sophisticated insulin pumps with the simplicity and affordability of pens and syringes, providing patients, physicians, and caregivers increas...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Diabetes Food & Drug Administration (FDA) Regulatory/Compliance Companion Medical Source Type: news

Mannkind taps medtech reps after Sanofi deal fails
Mannkind chief commercial officer Michael Castagna is trying to resuscitate the inhaled insulin maker after its co-marketing agreement with Sanofi (NYSE:SNY) was cancelled at the beginning of the year due to disappointing sales. He’s fielding a team of about 70 people to sell the company’s Afrezza insulin inhaler, with about ⅓ coming from the medical device industry. “We are looking to build a high energy nimble company that reflects the speed of the medical device industry, articulation of the science from biotech and a relentless focus on helping patients suffering from diabetes,” Castagna told ...
Source: Mass Device - June 28, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Business/Financial News Diabetes Drug-Device Combinations Mannkind Corp. Sanofi-Aventis newtag Source Type: news

Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
First insulin injection device to combine half-unit dosing with a memory function to help patients better manage their diabetes PLAINSBORO, N.J., Aug. 21, 2013 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk, a world leader in diabetes care, ... Biopharmaceuticals, Devices, Drug Delivery, FDANovo Nordisk, NovoPen Echo, NovoLog, insulin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 21, 2013 Category: Pharmaceuticals Source Type: news